Optimized Management of Nivolumab and Ipilimumab in Advanced Renal Cell Carcinoma: A Response-Based Phase II Study (OMNIVORE)

PURPOSE: In this phase II response-adaptive trial, we investigated the rational application of immune checkpoint blockade in renal cell carcinoma (RCC; ClinicalTrials.gov identifier: NCT03203473). METHODS: We enrolled patients with metastatic RCC with no prior checkpoint inhibitor exposure. All pati...

Descrición completa

Gardado en:
Detalles Bibliográficos
Publicado en:J Clin Oncol
Main Authors: McKay, Rana R., McGregor, Bradley A., Xie, Wanling, Braun, David A., Wei, Xiao, Kyriakopoulos, Christos E., Zakharia, Yousef, Maughan, Benjamin L., Rose, Tracy L., Stadler, Walter M., McDermott, David F., Harshman, Lauren C., Choueiri, Toni K.
Formato: Artigo
Idioma:Inglês
Publicado: American Society of Clinical Oncology 2020
Assuntos:
ORIGINAL REPORTS
Acceso en liña:https://ncbi.nlm.nih.gov/pmc/articles/PMC7768333/
https://ncbi.nlm.nih.gov/pubmed/33108238
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1200/JCO.20.02295
Tags: Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!

Títulos similares